Revance Therapeutics (RVNC) Stock Price, News & Analysis

Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Key Stats

• Today's Range: $3.65 to $3.65
• 50-Day Range: $3.04 to $3.68
• 52-Week Range: $2.30 to $7.56
• Volume: N/A
• Average Volume: 2.67 million shs
• Market Capitalization: $381.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.39
• Consensus Rating: Hold

Revance Therapeutics Stock Analysis - MarketRank™

Revance Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 164th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Revance Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Revance Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revance Therapeutics are expected to grow in the coming year, from ($1.57) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.32% of the outstanding shares of Revance Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Revance Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revance Therapeutics has recently decreased by 45.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revance Therapeutics does not currently pay a dividend.

Dividend Growth

Revance Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Percentage of Shares Shorted

4.32% of the outstanding shares of Revance Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Revance Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revance Therapeutics has recently decreased by 45.92%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 14 news articles for Revance Therapeutics this week, compared to 6 articles on an average week.

Search Interest

7 people have searched for RVNC on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

1 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revance Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.10% of the stock of Revance Therapeutics is held by insiders.

Percentage Held by Institutions

97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVNC Stock Analysis - Frequently Asked Questions

How have RVNC shares performed this year?

Revance Therapeutics' stock was trading at $3.04 at the beginning of 2025. Since then, RVNC stock has increased by 20.1% and is now trading at $3.65.
View the best growth stocks for 2025 here.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.12. The company's quarterly revenue was up 20.2% on a year-over-year basis.

Who are Revance Therapeutics' major shareholders?

Top institutional shareholders of Revance Therapeutics include Beryl Capital Management LLC (5.69%), Vanguard Group Inc. (5.39%), FIL Ltd (4.02%) and Alliancebernstein L.P. (3.35%). Insiders that own company stock include Mark J Foley, Tobin Schilke, Dustin S Sjuts, Dwight Moxie, Erica Jordan and Carey Oconnor Kolaja.
View institutional ownership trends.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RVNC
• CUSIP: N/A
• CIK: 1479290
• Web: www.revance.com
• Phone: (615) 724-7755
• Fax: 510-742-3401
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.39
• High Stock Price Target: $20.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +129.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-323,990,000.00
• Net Margins: -74.67%
• Pretax Margin: -122.07%
• Return on Equity: N/A
• Return on Assets: -37.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.12
• Quick Ratio: 3.05

Sales & Book Value

• Annual Sales: $234.04 million
• Price / Sales: 1.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.73) per share
• Price / Book: -2.11

Miscellaneous

• Outstanding Shares: 104,390,000
• Free Float: 99,066,000
• Market Cap: $381.02 million
• Optionable: Optionable
• Beta: 0.90